Repligen Corporation (NASDAQ:RGEN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jacob Johnson Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Leonard - UBS Investment Bank, Research Division Matthew Larew - William...
WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2025, covering the three- and nine- month periods ended September 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full...
Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET
Repligen Corporation (NASDAQ:RGEN ) Bank of America Global Healthcare Conference 2025 September 25, 2025 6:35 AM EDT Company Participants Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division Thanks, everyone, for j...
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.
Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base through a series of acquisitions and new launches, reducing its reliance on any single customer. RGEN stock is down 60% from its highs in the summer of 2021, and Repligen has a pristine balance sheet.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.